Skin sensitisation associated with allergic contact dermatitis is an important occupational and environmental disease. The identification of skin sensitisation hazards was traditionally performed using animal tests; originally guinea pig assays and subsequently the murine local lymph node assay (LLNA). More recently there has, for a variety of reasons, been an increased interest in, and requirement for, non-animal assays. There are now available both validated in vitro assays and a variety of approaches based on consideration of quantitative structure-activity relationships (QSAR). With the increased availability and use of non-animal alternatives for skin sensitisation testing there is a continuing need to monitor the performance of these approaches using series of chemicals that do not normally form part of validation exercises. Here we report studies conducted with 11 methacrylate esters and methacrylic acid in which results obtained with 3 validated in vitro tests for which there are OECD guidelines (the Direct Peptide Reactivity Assay, DPRA; ARE-Nrf2 luciferase test methods, and -with some chemicals -a dendritic cell activation test, the myeloid U937 Skin Sensitisation test [U-SENS] assay) have been compared with QSAR approaches (DEREK and TIMES-SS), and with LLNA and guinea pig maximisation test (GPMT) data. The conclusions drawn from these data are that -with this series of chemicals at least -there is a strong correlation between the results of animal tests and the in vitro assays considered, but not with either DEREK or TIMES-SS.
1. Introduction
General introduction
Skin sensitisation resulting in allergic contact dermatitis (ACD) is an important occupational and environmental health issue, and over one thousand chemicals have now been shown to have some potential to cause sensitisation (De Groot, 2008) . As an understanding of the cellular and molecular mechanisms that drive the acquisition of skin sensitisation and the elicitation of ACD has evolved, so opportunities to design and develop alternative (non-animal) approaches for the identification of skin sensitising chemicals have emerged. Enthusiasm for such new methods has been fuelled also by ethical considerations, and by changes in the regulatory and legislative landscapes. However, with the introduction of new paradigms for hazard identification and safety assessment, and a move away from methods based on experimental animals to in vitro and in silico approaches, there are inevitably challenges that need to be addressed. Against that background the purpose of this article is to review briefly the phenomenon of skin sensitisation, and the methods that are available for the purposes of hazard identification, and to consider how -in practice -such approaches perform in the context of one family of chemicals, the methacrylate esters.
Skin sensitisation
In common with other forms of allergic disease, ACD develops in two phases. In the first phase topical exposure of a susceptible subject to a sufficient concentration of a contact allergen induces immunological priming. This priming results in the acquisition of skin sensitisation. The second phase is triggered if the now sensitised subject is exposed to the same contact allergen, at the same or a different skin site. This results in elicitation of an accelerated and more aggressive secondary immune response causing local cutaneous inflammation at the site of contact that is recognised clinically as ACD (Rustemeyer et al., 2011; Kimber et al., 2011; Martin, 2015) .
The key molecular and cellular processes required for the development of skin sensitisation are relatively well understood and can be summarised briefly as follows. For the initiation of sensitisation it is necessary for the inducing chemical allergen to gain access to the viable epidermis via the stratum corneum. A central mandatory event is the creation of immunogenic complexes that require the stable association of the chemical with host proteins. This is necessary because low molecular weight chemicals are too small to be recognised effectively by the adaptive immune system. For this reason contact allergens are naturally electrophilic, or are converted to electrophilic species in the skin. Immunogenic chemical (hapten)-protein conjugates are recognised, internalised and processed by professional antigen presenting cells (Langerhans cells [LC] and other dendritic cells [DC] ) (Steinman and Cohn, 1973 ) that play pivotal roles in the initiation and subsequent regulation of adaptive immune responses. These cells, bearing antigen, are mobilised to migrate from the skin, via afferent lymphatics, to draining lymph nodes where responsive T lymphocytes are activated and triggered to divide and differentiate resulting in immune priming (Rustemeyer et al., 2011; Kimber and Dearman, 2002; Kimber et al., 2002a Kimber et al., , 2011 Kaplan et al., 2012; Ainscough et al., 2013; Martin, 2015) .
The main elements of the processes that result in the acquisition of skin sensitisation have been articulated in an Adverse Outcome Pathway (AOP). Such pathways are constructs that describe a series of linked events (known as Key Events or KE) that culminate in an adverse health effect (in this case ACD) (Ankley et al., 2010; Vinken, 2013) . The AOP for skin sensitisation is arguably the most fully developed (OECD, 2012; MacKay et al., 2013) . Full details of the skin sensitisation AOP are available elsewhere (OECD, 2012) , and for the purposes of this article it is necessary only to outline briefly the major components. These align closely with the sequence of events summarised above and that result in the stimulation of T lymphocyte responses and immunological priming.
The skin sensitisation AOP recognises 4 Key Events (KE) that are considered to be essential for the effective acquisition of sensitisation. In sequence these are: KE1 (the Molecular Initiating Event; MIE) -the formation of hapten-protein conjugates to create an immunogenic signal (the assumption being that the chemical has been able to gain access to the viable epidermis). As indicated above, this step may require the local conversion of a potentially allergenic chemical to an electrophilic species. KE2 -the elicitation of a local inflammatory response, involving keratinocytes, and possibly other skin cells, that results in the elaboration and release of signals (so-called 'danger signals'; Matzinger, 1994; McFadden and Basketter, 2000; Kimber et al., 2002b) . These signals promote and support the induction of an adaptive immune response. KE3 -the activation, differentiation and mobilisation of cutaneous DC such that they are fully equipped to process and transport antigen to regional lymph nodes where it is then presented to responsive T lymphocytes. KE4 -the activation, proliferation and differentiation of antigen-responsive T lymphocytes that results in the acquisition of skin sensitisation (OECD, 2012) .
The skin sensitisation AOP provides a useful model for describing the most important elements of the pathway that leads to the acquisition of sensitisation -and thereafter the elicitation of ACD. Moreover, it has facilitated the identification of those key events that should, in theory, represent the most relevant endpoints in the design of alternative methods for hazard identification. This theme will be returned to in the next section.
1.3. Predictive tests for skin sensitisation potential 1.3.1. Animal methods
Hazard identification was originally conducted using guinea pig tests; the guinea pig maximisation test (GPMT; Magnusson and Kligman, 1969) and the occluded patch test of Buehler (1965) being the most popular. Although guinea pig test methods differ with respect to protocols used, they are all based on assessment of sensitising potential as a function of challenge-induced cutaneous inflammatory reactions in previously sensitised animals. In the GPMT, the guinea pig method that has been considered here, induction of sensitisation is attempted using a combination of intradermal injection and topical exposure under occlusion, with the use of Freund's Complete Adjuvant (FCA) to 'maximise' responses (Magnusson and Kligman, 1969) .
Guinea pig tests were largely superseded by the mouse Local Lymph Node Assay (LLNA) Kimber et al., , 2002c Basketter et al., 2002) . This assay is based on measurement of the ability of topically applied test chemicals to induce the proliferation of lymphoid cells in draining lymph nodes; an endpoint that is known to be causally and quantitatively related to the induction of skin sensitisation (Kimber and Dearman, 1991) . In practice mice are exposed daily, for 3 consecutive days, to various concentrations of the test chemical, or to an equal volume of the relevant vehicle alone, on the dorsum of both ears. Five days following the initiation of exposure mice are injected intravenously with a source of tritiated thymdime ( 3 H-TdR), and 5 h later mice are sacrificed, the draining auricular nodes excised, and the proliferative activity of lymph node cells measured by β-scintillation counting (Kimber et al., 2002c) . Chemicals are identified as being skin sensitisers if they elicit a 3-fold or great increase in lymph node cell proliferative activity compared with concurrent vehicle controls. This assay, in addition to providing a method for hazard identification, permits evaluation of the relative skin sensitising potency of contact allergens (Kimber and Basketter, 1997; Kimber et al., 2002c) . For this purpose an EC3 value is derived, this being the concentration of chemical required to induce a 3-fold increase in proliferation. Various metrics can be used for expression of EC3 values: % concentration of chemical, the molar concentration, or the concentration per unit area of skin (Kimber et al., 2002c . In this review where EC3 values are cited it is the % concentration of chemical required to elicit a 3-fold increase in proliferative activity that has been recorded. The smaller the EC3 value, the greater is the sensitising potency of a contact allergen. Based on EC3 values it is possible to assign contact allergens to potency categories (Basketter et al., , 2005 Gerberick et al., 2001; Loveless et al., 2010) .
As indicated above, in recent years the field has moved on, and there has been considerable interest in the design and development of novel non-animal methods based on in vitro assay systems or quantitative structure-activity relationships (QSAR) (Adler et al., 2011) . The validated in vitro test methods will be considered first.
In vitro test methods
It is important to acknowledge that there is a variety of in vitro test methods that are currently in development, and some of these have potential merit and are candidates for validation in the future (Cottrez et al., 2016; Galbati et al., 2017 ) Nevertheless, attention here will focus on those approaches that have been validated formally, and for which there are OECD test guidelines. Before considering these individual methods it is relevant to point out that there is currently a view that no single in vitro method will alone have the performance characteristics required for accurate hazard identification. For this reason there have been attempts to consider how best results from two or more individual defined approaches can be integrated to provide a more reliable assessment of skin sensitising potential (Bauch et al., 2002; Van der Veen et al., 2014; Urbisch et al., 2015; Strickland et al., 2016; Ezendam et al., 2016; Asturiol et al., 2016) . An important caveat is, however, that combining the results from individual in vitro test methods may not necessarily result in improved prediction metrics .
Leaving aside consideration of whether integrated testing strategies represent a sound basis for assessment of sensitising activity, the focus here is to provide a short summary of the validated in vitro test methods as prelude to examining the activity of methacrylate esters in these assays. As will become clear below, each of the 3 approaches considered here is considered to reflect (to a greater or lesser extent) one of the Key Events in the AOP for skin sensitisation. The approaches are as follows:
The Direct Peptide Reactivity Assay (DPRA; OECD TG 442C) (reflecting KE1 of the skin sensitisation AOP -haptenation of skin proteins). The DPRA evaluates the ability of test chemicals to form stable (covalent) associations with host proteins. In practice, the assay is based upon measurement of the depletion of peptides incorporating either a cysteine or lysine following incubation with the test chemical (Gerberick et al., 2004 (Gerberick et al., , 2007 ; OECD, 2015a).
The second approach embraces the KeratinoSens and LuSens assays (ARE-Nrf2 Luciferase test methods; OECD TG 442D) (reflecting KE2 of the AOP -generation of danger signals). In common with the DPRA, this approach is based upon the electrophilic activity of sensitising chemicals. The tests exploit the Nrf2-Keap-1-antioxidant response element (ARE) pathway that is triggered by the covalent interaction of electrophilic skin sensitising chemicals with the Keap-1 protein (Ade et al., 2009 ). Evaluations are conducted using a keratinocyte cell line containing a luciferase reporter gene under the control of an ARE which senses and responds to protein-reactive skin sensitising chemicals (Emter et al., 2010; Natsch and Emter, 2016; Ramirez et al., 2014; OECD, 2015b OECD, , 2018a .
The final approach is based on the activation of DC (OECD TG 442E) (reflecting KE3 of the AOP -activation of DC). The strategy here is to evaluate the ability of test chemicals to stimulate the elevated expression of membrane determinants, or of soluble cell products, indicative of the activation of DC-like cells in vitro. The specific assays embraced by this OECD test guideline are: (a) the human Cell Line Activation Test (h-CLAT) in which the ability of test chemicals to induce the elevated expression of activation markers (CD54 and/or CD86) is measured using a human monocytic leukaemia cell line (THP-1) as a surrogate for DC (Ashikaga et al., , 2010 Sakaguchi et al., 2006; Nukada et al., 2012; OECD, 2018b) ; (b) the Myeloid U937 Skin Sensitisation Test (U-SENS) method, which is similar in principle to h-CLAT, and measures chemical-induced changes in the expression of CD86 on a histiocytic lymphoma cell line U937 Pirorid et al., 2015; OECD, 2018b) ; and (c) the IL-8-Luc assay in which changes in the expression of the cytokine interleukin 8 (IL-8) are measured (using a THP-1 cell line expressing a reporter gene) as a function of luciferase expression (Takahashi et al., 2011; Kimura et al., 2015; OECD, 2018b ).
QSAR approaches
There has been a long-standing and continuing interest in the use of QSAR systems to predict toxic activity, including the potential of chemicals to induce skin sensitisation. These systems have matured and evolved as an understanding of the chemical bases for sensitising activity, and of structural alerts, has increased (Dupuis and Benezra, 1982; Basketter and Roberts, 1990; Cronin and Basketter, 1994; Barratt et al., 1994; Ashby et al., 1995; Aptula et al., 2005; Patlewicz et al., 2007a; Fitzpatrick et al., 2018) .
Two QSAR systems have been employed here to evaluate the sensitising potential of selected methacrylate esters; DEREK™ (DEREK TMnexus; specifically version DEREK™ Nexus v.4.1.0; Nexus: 2.0.0) and TIMES-SS. DEREK™, (originally an acronym for Deductive Estimation of Risk from Existing Knowledge) (Sanderson and Earnshaw, 1991) , has been evaluated extensively -in various manifestations -for the purposes of identifying skin sensitising chemicals (Barratt and Langowski, 1999; Langton et al., 2006; Patlewicz et al., 2007a; Ellison et al., 2009; Macmillan et al., 2016; Fitzpatrick et al., 2018) . DEREK TM -nexus is a rule-based expert system incorporating multiple structural alerts that seeks to identify skin sensitisation hazards. TIMES-SS (the Times Metabolism Simulator platform for predicting Skin Sensitisation) is a hybrid expert system that encodes skin-toxicity and skin-metabolism relationships through a number of transformations simulating skin metabolism and the interaction of generated reactive species with skin proteins. It was developed using training set data derived from both the GPMT and LLNA, and the stated aim is to support prediction of pre-and pro-electrophilic activation of chemicals as part of skin sensitisation assessment (Patlewicz et al., 2007b (Patlewicz et al., , 2014 Roberts et al., 2007; Urbisch et al., 2016; Fitzpatrick et al., 2018) .
Assessment of the skin sensitisation potential of methacrylate esters

The methacrylate esters
A series of 11 methacrylate esters and methacrylic acid have been considered in this review. Only methacrylic acid and simple linear or branched alkyl methacrylates without additional rings, heteroatoms (other than oxygen) or reactive functional groups were included. Details of the names, acronyms and CAS numbers of these compounds are provided in Table 1 .
Assessments using animal methods
Guinea pig (GPMT) and/or LLNA data were available for 11 of the 12 compounds considered here. A summary of the results of these assays is provided in Table 2 . LLNA data for 10 of the 12 compounds were available. Five of these compounds displayed positive (albeit weak) responses, and 5 were negative (non-sensitisers). Data from GPMT studies were available for 7 compounds. Of these 1 was found to be a sensitiser, 5 were non-sensitisers, and for one compound variable results have been recorded (Table 2) . It is important to emphasise that, in common with previous analyses (Kimber and Pemberton, 2014) , even when responses in the LLNA or GPMT studies would trigger classification as a skin sensitiser, the sensitisation potency of methacrylate esters is almost invariably low. For example, the following EC3 values were recorded for the 5 compounds identified as eliciting positive responses in the LLNA: MMA -60-90% (Betts et al., 2006) , EMA -83% (Harlan, 2013a) , n-BMA -44% (Harlan, 2013b) , i-BMA -41% (Harlan, 2013c) , n-OMA -32% (JRF, 2018b). These are all values indicative of weak skin sensitising activity (Kimber et al., 2003; Loveless et al., 2010) .
The picture is similar with the GPMT. One compound that elicited a clear positive response in the GPMT was MMA, but this required high concentrations of the test material at both the induction and challenge phases (Boman et al., 1996) . Data available for MMA in the GPMT have been reviewed elsewhere, and the conclusion drawn is that the results are indicative of a weak skin sensitising potential, with a significant number of assays in fact yielding negative results (Borak et al., 2011; Kimber and Pemberton, 2014) . With EMA very variable -and at most very weak -responses have been recorded with the GPMT, and the on the basis of these data EMA would not be classified as a skin sensitiser (Kimber and Pemberton, 2014) . Finally, variable responses have been recorded with EHMA, and even when positive results have been reported they were of low grade indicative of, at most, very weak skin sensitising potential (Kimber and Pemberton, 2014) . It should be noted that, although (as indicated in Table 2 ) there are no GPMT studies available for MAA, the results of a Buehler assay have been reported. Based on that study MAA was found not to be a skin sensitiser (Dupont, 1993) .
Assessments using in vitro methods
For the purposes of these analyses, a total of 4 validated OECD guideline methods were used: DPRA (reflecting KE1 of the skin sensitisation AOP), LuSens or KeratinoSens (reflecting KE2), and U-SENS (reflecting KE3). With the latter method data are available for only 3 chemicals. Results obtained with the 12 selected compounds are summarised in Table 3 . For ease of comparison LLNA data have been shown alongside the results of the in vitro tests.
Methacrylic acid (MAA) was negative in both the DPRA and in the KeratinoSens assay; data that are consistent with the results of a Buehler test cited above, and with the fact that MAA is a free acid lacking electrophilic activity.
Four compounds (MMA, EMA, n-BMA and i-BMA) were each positive in the DPRA and in the LuSens (MMA, EMA and n-BMA) or KeratinoSens (iBMA) methods. In addition, MMA, EMA and n-BMA were each positive in U-SENS. Data from U-SENS were unavailable for i-BMA (Table 3) . It is clear from the results summarised in Table 3 that there was complete concordance between the LLNA and the results of each of the in vitro tests used here; with all test methods MMA, EMA, n-BMA and i-BMA elicited positive responses.
Three other compounds were found to be negative in all tests for which data are available. Thus, n-HMA, EHMA and IDMA were each negative in the DPRA, the KertinoSens method, and in the LLNA (Table 3) .
With some other compounds, differences between test methods were observed. Thus, n-OMA was shown to be a weak skin sensitiser in the LLNA, but was negative in both the DPRA and KeratinoSens assay. In contrast, LMA and TDMA C13MA were negative in the LLNA and the DPRA, but elicited weak positive responses in the KeratinoSens assay (Table 3) .
For t-BMA insufficient data were available to draw comparisons (Table 3) .
Assessments using QSAR
Results obtained with DEREK TM -nexus and TIMES-SS are summarised in Table 4 and compared with the relevant LLNA data.
With the exception of MAA, DEREK™ predicted all of the compounds to have a skin sensitisation alert. In all instances (other than with MAA) the prediction was 'Plausible', defined as 'the weight of evidence supports the proposition' (of skin sensitising activity). Skin sensitising potential was inferred from the presence in each case of an alpha/beta-unsaturated ester. DEREK™ did not identify MAA as a skin sensitiser which is consistent with this being a free acid (lacking electrophilic activity), rather than an ester (Table 4) .
With TIMES-SS MAA was also negative, as were 5 other compounds (MMA, EMA, n-BMA, LMA and TDMA C13MA). In contrast, the other 6 compounds (i-BMA, t-BMA, n-HMA, EHMA, n-OMA and IDMA) were judged to be weak positives (Table 4) .
Discussion
The drive towards the design and development of alternative (nonanimal) approaches for skin sensitisation testing has resulted in a wide array of new in vitro methods, some of which have been validated and are embraced by OECD test guidelines. Despite this undoubted progress, there is currently a view that these tests are individually inadequate for the reliable assessment of skin sensitisation potential (Bauch et al., 2002; Reisinger et al., 2015; Asturiol et al., 2016) . For this reason there has been considerable interest in exploring how novel in vitro methods might be incorporated into integrated testing strategies Table 3 Activity of methacrylate esters and methacrylic acid in in vitro tests for skin sensitisation (DPRA, LuSens/KeratinoSens and U-SENS); comparison with LLNA data. Positive (K) a n/a Sensitiser t-BMA n/a Equivocal (K) a n/a n/a n-HMA Negative with improved predictive power (Bauch et al., 2002; Van der Veen et al., 2014; Urbisch et al., 2015; Strickland et al., 2016; Ezendam et al., 2016) . This strategy appears logical. However, it has been pointed out recently that combining data from individual defined approaches may not necessarily result in improved predictivity . It should also be borne in mind that novel in vitro tests (such as those identified currently in OECD test guidelines) that are predicated on evaluation of individual KEs of the AOP may not always adequately reflect skin sensitising activity. The acquisition of skin sensitisation is an extremely complex and tightly regulated biological process that requires highly coordinated interactions between a variety of cells and molecules. Consequently, there are real difficulties in distilling this level of biological complexity into simple in vitro endpoints that will provide an accurate reflection of skin sensitisation potential. It is, therefore, a real achievement that those methods considered here, that are designed to determine the ability of chemicals to form covalent associations with protein, or to elicit danger signals from keratinocytes, or to activate DC, perform sufficiently well to have achieved validation. However, as indicated above, the predictive power of such methods may be somewhat limited, especially when used in isolation. Consequently, it is important that the performance of these in vitro assays is evaluated with chemicals that do not normally form part of validation series.
With the compounds that have been the subject of comparative evaluations reported here (11 methacrylate esters and methacrylic acid) the LLNA database was more complete than was that for the GPMT. In general it can be concluded that the LLNA was found with this series to be the more sensitive of the 2 methods. Thus, MMA, EMA, n-BMA and i-BMA all tested positive in the LLNA, but only MMA gave a positive response in the GPMT. The higher molecular weight (MW) methacrylate esters that were tested in the LLNA (n-HMA, EHMA, n-OMA, IDMA, LMA and TDMA C13MA) were all found to be negative with the exception of n-OMA. The reason for the unexpected positive response in the LLNA with n-OMA is not known. However, with that exception, the general negative correlation between increasing MW and activity in the LLNA is probably related to poor dermal flux and the inability of higher MW esters to adequately gain access to the viable epidermis. Indeed, a strong positive association between sensitising potential as measured in the LLNA and predicted dermal flux has been found within this series of methacrylate esters (data not presented). In addition, it should be borne in mind that metabolic detoxification (enzymatic hydrolysis) may also impact on skin sensitising potential (Gelbke et al., 2018) .
There was a strong correlation between responses in the LLNA and activity in the DPRA. The lower MW esters (MMA, EMA, n-BMA and i-BMA) were each positive in both assays, whereas the higher MW compounds were negative in the DPRA and (with the exception of n-OMA) in the LLNA. A similar correlation was recorded when responses in the LLNA were compared with those in the ARE-Nrf2 test methods. Again, positive responses were obtained in both methods with MMA, EMA, n-BMA and i-BMA, whereas the higher MW esters gave either negative responses -or only weak positive responses -in the ARE-Nrf2 methods, and negative responses (with the exception of n-OMA) in the LLNA.
The conclusion drawn from these comparative analyses is thatwithin this series of chemicals at least -there is a clear correlation between activity in the LLNA and responses in the DPRA and ARE-Nrf2 methods. It is assumed that the higher MW esters tested here fail to display skin sensitising potential for at least 2 reasons: first, because they fail to gain adequate access to the viable epidermis, and second, because they do not form stable associations with protein (a prerequisite for positive responses in both the DPRA and ARE-Nrf2 methods).
There are insufficient data to draw inferences regarding the correlation between the U-SENS method and other assays, although it was observed that the 3 low MW esters for which data were available elicited positive responses in the U-SENS assay (and in the LLNA).
Comparative analyses of QSAR methods were less encouraging. Using DEREK™, all methacrylate esters were judged to have skin sensitisation alerts -with a classification of 'Plausible' -based on the presence in each instance of an alpha/beta-unsaturated ester. This consistent over-prediction of the higher MW esters indicates that this structural alert is not translated into a skin sensitising potential, possibly because of poor epidermal bioavailability.
The sensitivity of TIMES-SS was low (only 1 of 4 compounds found to be positive in the LLNA was identified as a weak positive), and the overall correlation with LLNA data was poor. The reasons for this are not entirely clear.
Conclusions
Comparative analyses using a series of methacrylate esters have shown a strong correlation between results obtained using the LLNA and activity in 2 novel non-animal approaches for which OECD test guideless are available (DPRA and ARE-Nrf2 methods). These data are encouraging insofar as they show concordance between various methods for the identification of skin sensitisation hazards.
Comparisons with human data were not a major theme of these investigations. Nevertheless, it is relevant to report that, with respect to the lower alkyl methacrylate esters at least (for which comparative data are available), the results obtained with MMA, EMA, n-BMA, i-BMA and EHMA in the LLNA, DPRA and ARE-Nrf2 methods align closely with available human data (Kimber and Pemberton, 2014; Gelbke et al., 2018) .
Data obtained using 2 QSAR methods (DEREK™ and TIMES-SS) were less encouraging, and failed to reflect results recorded with in vivo or in vitro test methods, or with available human data. It is probable that -in this chemical series at least -structural alerts fail to predict accurately the acquisition of skin sensitisation potential for a variety of reasons, including the level of dermal flux, local skin metabolism and/or an inability to elicit danger signals or to activate DC.
Taken together, the data indicate that, in the case of the methacrylate esters considered here, some novel in vitro tests provide a reliable indication of skin sensitisation potential, but that QSAR methods (at least those employed in these analyses), fail to do so.
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